Form 4: Vir Biotechnology Director Vicki Sato Boosts Stake with RSU Acquisition and Stock Option Grant

Vir Biotechnology, Inc. Director Vicki L. Sato acquired 8,000 restricted stock units and was granted 16,000 stock options, increasing her beneficial ownership in the company.

Summary

• Vicki L. Sato, a Director of Vir Biotechnology, Inc. (VIR), acquired 8,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 30, 2025.
• These RSUs were acquired at a price of $0 and are part of the Issuer's Equity Incentive Plan.
• The 8,000 RSUs will vest in full on May 30, 2026.
• Following this transaction, Ms. Sato beneficially owns 1,320,391 shares of Common Stock.
• Additionally, Ms. Sato was granted 16,000 stock options with an exercise price of $4.94 on May 30, 2025.
• These stock options will vest and become exercisable in full on May 30, 2026, and have an expiration date of May 29, 2035.
• After this grant, Ms. Sato beneficially owns 16,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units and grant of stock options to a director is a positive signal, indicating alignment of interests and confidence in the company's future. It's a standard compensation practice, hence not extremely high, but still positive.

Positives

• A Director, Vicki L. Sato, acquired 8,000 Restricted Stock Units (RSUs) and was granted 16,000 stock options, indicating continued alignment of management interests with shareholders.
• The acquisition of RSUs at $0 and the grant of stock options are part of the company's Equity Incentive Plan, which is a common mechanism to incentivize and retain key personnel.

Future Outlook

The vesting schedule for the acquired RSUs and granted stock options on May 30, 2026, indicates a future incentive for the director to remain with and contribute to the company's performance.

Industry Context

This Form 4 filing reflects a routine insider transaction for a biotechnology company, where equity grants are a standard component of director compensation and incentive structures. Such grants are common across the industry to align the interests of directors and executives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders, potentially signaling confidence and long-term commitment.

Next Steps

• The 8,000 Restricted Stock Units (RSUs) are scheduled to vest in full on May 30, 2026.
• The 16,000 stock options are scheduled to vest and become exercisable in full on May 30, 2026.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, Vicki Sato, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director Compensation, Beneficial Ownership